Barclays
RNA icon

Barclays’s Atrium Therapeutics RNA Stock Holding History

Barclays’s Portfolio RNA Stock Details RNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$48.6K Buy
5,856
+3,157
+117% +$37.2K ﹤0.01% 4581
2026
Q2 		$35.8K Buy
2,699
+604
+29% +$7.89K ﹤0.01% 4431
2026
Q1 		$28K Buy
+2,095
New +$29.4K ﹤0.01% 4498

Other funds holding RNA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Trium Capital
Trium Capital London, United Kingdom $79.4M AUM 36.67% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
AlphaCentric Advisors
AlphaCentric Advisors San Juan, Puerto Rico $113M AUM 27.37% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Kestra Private Wealth Services
Kestra Private Wealth Services Austin, Texas $9.37B AUM 22.72% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return
STRS Ohio
STRS Ohio Columbus, Ohio $27.1B AUM 34.64% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $191B AUM 30.51% 1-Year Est. Return

Barclays's RNA Position: Q3 2026 in Review

Barclays increased its Atrium Therapeutics (RNA) stake by 117% in Q3 2026, buying an estimated $37.2K and bringing the position to 5,856 shares worth $48.6K. The position accounts for ﹤0.01% of the portfolio, ranked #4581.

Barclays first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. 33 funds tracked by Wall St. Rank hold RNA as of Q3 2026.

  • Barclays held 5,856 shares of Atrium Therapeutics worth $48.6K as of Q3 2026.
  • Barclays bought 3,157 Atrium Therapeutics shares in Q3 2026, an estimated $37.2K.
  • Atrium Therapeutics made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #4581 holding.
  • Barclays first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • 33 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.

Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.